These medicinal products require prescription either by primary care physicians or by specialists or form an integral part of hospital treatment.
Prescription Medicines, which represents the bulk of our Human Pharmaceuticals
business, accounts for 78 percent of our total net sales and generated EUR 11,4 billion in 2012.
Boehringer Ingelheim's product portfolio covers the following main indications:
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products.
Where appropriate and possible, Boehringer Ingelheim and its locations around the world will continue to provide more detailed information specifically for your geographic region while meeting the regulations of the local authorities. You are welcome to visit the websites of our local affiliates.
For specific questions on our products, please contact us.
If you are seeking advice on any specific medical concern or treatment please consult your health care professional.